Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes

Journal of Clinical Biochemistry and Nutrition

Volumn 53, Issue 1, 2013, Pages 68-72

  Matsumoto, Shinobu ^a   Yamazaki, Masahiro ^a   Kadono, Mayuko ^a   Iwase, Hiroya ^a   Kobayashi, Kanae ^a   Okada, Hiroshi ^a   Fukui, Michiaki ^a   Hasegawa, Goji ^a   Nakamura, Naoto ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Continuous glucose monitoring; Glucagon; Insulin; Liraglutide; Test meal

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN; LIRAGLUTIDE; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; COMPARATIVE STUDY; DIABETIC PATIENT; DRUG EFFECT; GLYCEMIC CONTROL; HORMONE RESPONSE; HOSPITAL PATIENT; HUMAN; INJECTION; INSULIN RELEASE; INSULIN TREATMENT; JAPANESE; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; TEST MEAL; TREATMENT DURATION;

EID: 84881294323     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.13-14     Document Type: Article

References (21)

1. Pfeifer MA, Halter JB, Prote D Jr. Insulin secretion in diabetes mellitus. Am J Med 1981;70:579-588.
2. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal α-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970;283:109-115.
3. Dunning BE, Gerich JE. The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007;28:253-283.
4. Hoist JJ, Orskov AC, Nielsen OV, Schwartz TW. Truncated glucagon-Iike peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987;211:169-174.
5. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36:a physiological incretin in man. Lancet 1987;2:1300-1304.
6. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705.
7. Willms B, Werner J, Hoist JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucogon-like peptide-1 (GLP-1) - (7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996;81:327-332.
8. Nauck MA, Wollschäger D, Werner J, et al. Effects of subcutaneous glucagonlike peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996;39:1546-1553.
9. Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther 2011;28:213-226.
10. Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clin Sci 1998;95:325-329.
11. Nicolaus M, Brödl J, Linke R, Woerle HJ, Göke B, Schirra J. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab 2011;96:229-236.
12. Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010;1:212-228.
13. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002;51:424-429.
14. Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on P-cell function in normal living conditions. Diabetes Care 2007;30:2032-2033.
15. De Heer J, Hoist JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007;56:438-443.
16. D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab 2011;13:126-132.
17. Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther 2011;28:213-226.
18. Mori Y, Taniguchi Y, Sezaki K, Yokoyama J, Utsunomiya K. Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study. Diab Technol Ther 2011;13:1139-1144.
19. Kozawa J, Inoue K, Iwamoto R, et al. Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity. J Diab Invest 2011;3:294-297.
20. Iwao T, Sakai K, Sata M. Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes. J Diabetes Complications 2013;27:87-91.
21. Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 2011;7:507-516.